质子化学位移成像研究联合抗逆转录病毒治疗对慢性HIV感染神经代谢参数的影响
本研究采用二维质子化学位移成像,比较31例接受联合抗逆转录病毒治疗的慢性HIV感染者、19例未治疗的慢性HIV感染者与41例健康对照的脑代谢物比值,发现接受与未接受治疗的患者多个脑区NAA/Cr均显著降低,两组患者间脑代谢物比值无显著差异,CNS穿透效能评分仅与部分区域Cho/Cr弱正相关。
要点
- 慢性HIV感染者无论是否接受联合抗逆转录病毒治疗,额叶和顶叶皮层下白质及扣带回灰质NAA/Cr均较健康对照显著降低(P<.05)。
- 接受与未接受联合抗逆转录病毒治疗的慢性HIV感染者之间,脑代谢物比值无显著差异。
- CNS穿透效能评分仅与部分位置Cho/Cr比值呈弱正相关。
核心结论
- 联合抗逆转录病毒治疗在成功抑制外周病毒复制的慢性HIV感染中,对神经元丢失和功能障碍过程的影响似乎欠佳;波谱成像可能有助于监测不同联合抗逆转录病毒治疗方案对脑代谢物比值的影响。
研究设计与样本
- 研究纳入91名受试者,包括31例接受联合抗逆转录病毒治疗的慢性HIV感染者、19例未接受联合抗逆转录病毒治疗的慢性HIV感染者和41例健康对照,采用二维化学位移成像覆盖额叶和顶叶皮层下白质及扣带回灰质,长TE分析NAA/Cr和Cho/Cr比值,短TE分析mIns/Cr比值,并将神经代谢参数与免疫学、临床数据及联合抗逆转录病毒治疗效能评分进行相关性分析。
关键影像表现/征象
- 在全部检测位置,接受和未接受联合抗逆转录病毒治疗的HIV阳性患者NAA/Cr均较健康对照显著降低(P<.05)。
- 接受和未接受联合抗逆转录病毒治疗的HIV阳性患者与健康对照相比,Cho/Cr(P<.05)和mIns/Cr(P<.05)比值存在显著差异,但分布不同。
- 两组慢性HIV感染者之间脑代谢物比值无显著差异。
诊断标准与关键数值
- 以NAA/Cr、Cho/Cr(长TE)和mIns/Cr(短TE)比值作为神经代谢参数,与健康对照比较。
- CNS穿透效能评分仅与部分位置Cho/Cr比值呈弱正相关。
临床应用与阅片要点
- 慢性HIV感染者即使接受联合抗逆转录病毒治疗且外周病毒复制被成功抑制,NAA/Cr仍可降低,提示存在神经元损伤或功能障碍。
- 波谱成像可能作为监测不同联合抗逆转录病毒治疗方案对脑代谢物比值影响的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The introduction of combination antiretroviral therapy has failed to reduce the high prevalence of mild forms of HIV-associated neurocognitive disorders. The aim of this study was to test the effect of combined antiretroviral therapy on brain metabolite ratios in chronic HIV infection by using proton chemical shift imaging.
MATERIALS AND METHODS: We performed 2D chemical shift imaging in 91 subjects (31 HIV+ patients with chronic infection on combination antiretroviral therapy, 19 combination antiretroviral therapy-naïve HIV+ subjects with chronic infection, and 41 healthy controls), covering frontal and parietal subcortical white and cingulate gyrus gray matter, analyzing ratios of NAA/Cr and Cho/Cr on long-TE and mIns/Cr on short-TE MR spectroscopy. We correlated neurometabolic parameters with immunologic, clinical, data and combined antiretroviral therapy efficacy scores.
RESULTS: There was a significant decrease in NAA/Cr (P < .05) in HIV-positive patients on and without combined antiretroviral therapy, compared with healthy controls in all locations. There were significant differences in Cho/Cr (P < .05) and mIns/Cr (P < .05) ratios between HIV+ patients on and without therapy, compared with healthy controls, but these differed in distribution. There were no significant differences in brain metabolite ratios between the 2 groups of chronically HIV-infected patients. The CNS penetration efficacy score showed weak positive correlations only with Cho/Cr ratios in some locations.
CONCLUSIONS: The impact of combined antiretroviral therapy on the process of neuronal loss and dysfunction in chronic HIV infection appears to be suboptimal in successful peripheral suppression of viral replication. Spectroscopic imaging might be a useful tool for monitoring the effects of different combined antiretroviral therapy regimens on brain metabolite ratios.
引用
- Boban J, Kozic D, Turkulov V, et al. Proton Chemical Shift Imaging Study of the Combined Antiretroviral Therapy Impact on Neurometabolic Parameters in Chronic HIV Infection. AJNR Am J Neuroradiol. 2017. PMID: 28428210. doi:10.3174/ajnr.A5160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。